DKAH 3 CL
Latest Information Update: 30 May 2001
At a glance
- Originator Boehringer Ingelheim Pharma KG
- Class Antiarrhythmics
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
Most Recent Events
- 30 May 2001 Profile reviewed but no significant changes made
- 15 Oct 1994 No-Development-Reported for Arrhythmias in Germany (PO)